Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000799151 | SCV000938802 | pathogenic | Mucopolysaccharidosis, MPS-IV-B; GM1 gangliosidosis | 2020-01-11 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GLB1 protein function. This variant has been observed in individual(s) with GM1-gangliosidosis (Invitae). In at least one individual the data is consistent with the variant being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 645125). This variant is not present in population databases (ExAC no frequency). This sequence change replaces proline with histidine at codon 566 of the GLB1 protein (p.Pro566His). The proline residue is highly conserved and there is a moderate physicochemical difference between proline and histidine. |